Corcept Therapeutics INC (CORT) Holder Federated Investors INC Has Trimmed Its Position by $9.97 Million

Corcept Therapeutics Incorporated (NASDAQ:CORT) LogoInvestors sentiment increased to 0.93 in Q2 2019. Its up 0.12, from 0.81 in 2019Q1. It increased, as 23 investors sold CORT shares while 51 reduced holdings. 19 funds opened positions while 50 raised stakes. 82.53 million shares or 2.05% less from 84.26 million shares in 2019Q1 were reported. Blair William & Company Il holds 0% or 26,005 shares. First Advsrs LP holds 0% or 12,297 shares. Tower Limited Liability Corp (Trc) accumulated 679 shares. Zurcher Kantonalbank (Zurich Cantonalbank) reported 6,015 shares or 0% of all its holdings. Moreover, Ubs Asset Mgmt Americas has 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT). Geode Capital Mngmt Limited Liability Corp accumulated 1.38 million shares or 0% of the stock. Gotham Asset Mngmt Ltd Company owns 76,187 shares. Great West Life Assurance Commerce Can accumulated 139,501 shares. South Dakota Invest Council reported 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Public Employees Retirement System Of Ohio holds 0% or 44,710 shares in its portfolio. Aqr Capital Mngmt Limited Liability Corporation holds 201,062 shares or 0% of its portfolio. Guggenheim Limited Company invested in 21,703 shares or 0% of the stock. The New York-based Jpmorgan Chase And has invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Sei Invests accumulated 53,271 shares. State Of Alaska Department Of Revenue holds 0.01% or 35,580 shares in its portfolio.

Federated Investors Inc decreased its stake in Corcept Therapeutics Inc (CORT) by 8.11% based on its latest 2019Q2 regulatory filing with the SEC. Federated Investors Inc sold 906,189 shares as the company’s stock declined 8.68% . The institutional investor held 10.27M shares of the major pharmaceuticals company at the end of 2019Q2, valued at $114.51M, down from 11.18 million at the end of the previous reported quarter. Federated Investors Inc who had been investing in Corcept Therapeutics Inc for a number of months, seems to be less bullish one the $1.52 billion market cap company. It closed at $13.37 lastly. It is down 12.17% since September 13, 2018 and is downtrending. It has underperformed by 12.17% the S&P500.

Federated Investors Inc, which manages about $41.20 billion US Long portfolio, upped its stake in Penumbra Inc by 19,800 shares to 230,100 shares, valued at $36.82 million in 2019Q2, according to the filing. It also increased its holding in Forescout Technologies Inc by 157,139 shares in the quarter, for a total of 322,139 shares, and has risen its stake in Ssga Active Etf Tr (SRLN).

Analysts await Corcept Therapeutics Incorporated (NASDAQ:CORT) to report earnings on November, 7. They expect $0.20 earnings per share, up 42.86 % or $0.06 from last year’s $0.14 per share. CORT’s profit will be $22.74M for 16.71 P/E if the $0.20 EPS becomes a reality. After $0.17 actual earnings per share reported by Corcept Therapeutics Incorporated for the previous quarter, Wall Street now forecasts 17.65 % EPS growth.

More notable recent Corcept Therapeutics Incorporated (NASDAQ:CORT) news were published by: which released: “Lawsuit for Investors in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) announced by Shareholders Foundation – Yahoo Finance” on May 20, 2019, also with their article: “Is Corcept Therapeutics Incorporated’s (NASDAQ:CORT) CEO Overpaid Relative To Its Peers? – Yahoo Finance” published on August 27, 2019, published: “Corcept nabs U.S. patent covering Korlym with food –” on August 28, 2019. More interesting news about Corcept Therapeutics Incorporated (NASDAQ:CORT) were released by: and their article: “Corcept Therapeutics And Relacorilant In Cushing’s Syndrome – Seeking Alpha” published on August 26, 2019 as well as‘s news article titled: “Corcept Therapeutics Q1 2019 Earnings Preview – Seeking Alpha” with publication date: May 08, 2019.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.